黛力新治疗伴焦虑抑郁症重度COPD疗效观察

目的 探讨加用黛力新治疗伴焦虑抑郁症的重度慢性阻塞性肺疾病(COPD)患者的疗效.方法 将2011年12月至2014年12月在我院确诊为伴焦虑抑郁症重度COPD患者198例按入院时间顺序,分为对照组(2011年12月至2013年8月入院者)和治疗组(2013年9月至2014年12月入院者)各99例.对照组采用常规方法治疗,治疗组在对照组治疗的基础上加用黛力新1片口服,1次/d,两组疗程均为30 d.比较两组患者治疗前后的焦虑抑郁评定(HAMA评分)、肺通气功能变化、COPD症状评估测试(CAT评分),同时评价两组患者治疗后的疗效.结果 经过黛力新治疗30 d后,治疗组患者的HAMA评分为(15.40±3.32)分,明显低于对照组的(22.16±4.26)分,差异具有统计学意义(P<0.05);治疗组患者经治疗后的各项肺通气功能指标[一秒量比预计值(FEV1%pred)=(50.31 ± 4.17);一秒量比用力肺活量(FEV1/FVC)=(63.8 ± 1.89);肺活量(VC)=(2.95 ± 0.35) L]较对照组[(FEV1%pred=(42.31 ± 4.17);FEV1/FVC=(58.49 ± 2.35);VC=(1.86 ± 0.19) L]均明显上升、CAT评分[(14.49 ± 3.16)分]比对照组(16.68±4.28)分显著下降、临床疗效治疗组总有效率显著上升[治疗组87.88%(87/99),对照组20.20%(20/99)],两组比较差异均具有统计学意义(P<0.05).治疗组治疗过程中未出现明显不良反应.结论 黛力新辅助治疗存在焦虑抑郁等不良情绪的重度COPD患者具有良好的临床疗效,其不仅改善慢性阻塞性肺疾病的临床症状,同时还减轻焦虑抑郁症状,且安全性较高,可以提高COPD患者生活质量,值得进行临床推广应用.

Curative effect of Deanixit in the treatment of severe chronic obstructive pulmonary disease with anxiety and depression

Objective To investigate the curative effect of the anti-anxiety drug (Deanxit) in the treatment of pa-tients with severe chronic obstructive pulmonary disease (COPD) complicating anxiety and depression. Methods One hundred and ninety-eight patients with severe COPD complicating anxiety and depression from Dec. 2011 to Dec. 2014 were enrolled and divided into two groups according to admission time:study group (Sep. 2013 to Dec. 2014) and con-trol group (Dec. 2011 to Aug. 2013). The control group applied routine treatment, and the study group was given one piece of Deanxit orally once per day based on the treatment of the control group. The treatment course was 30 days. The Hamilton Anxiety Scale (HAMA) score, changes in pulmonary ventilation function, COPD Assessment Test (CAT score), as well as clinical efficacy were compared between the two groups. Results After treatment, HAMA score in the study group [(15.40±3.32)] was significantly lower than (22.16±4.26) in the control group (P<0.05). The pulmonary ventilation function indexes in the study group, including forced expiratory volume in one second as a percentage of pre-dicted (FEV1%pred), forced expiratory volume in one second/forced vital capacity (FEV1/FVC) and vital capacity (VC), were significantly improved compared with those in the control group (P<0.05), which were (50.31±4.17) vs (42.31±4.17), (63.8±1.89) vs (58.49±2.35), and (2.95±0.35) vs (1.86±0.19), respectively. CAT scores and clinical efficacy of the study group were also significantly improved, (14.49 ± 3.16) vs (16.68 ± 4.28) and 87.88%(87/99) vs 20.20%(20/99) (P<0.05), No obvious adverse reactions were observed in the study group. Conclusion For the patients of COPD with anxiety and depression, Deanxit can improve the clinical symptoms, relieve anxiety and depression, and improve the life of quali-ty of the patients, with good safety, which is worthy of clinical promotion.